Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Jul;31(7):1010–1013. doi: 10.1128/aac.31.7.1010

Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.

T C Gasser 1, P H Graversen 1, P O Madsen 1
PMCID: PMC174862  PMID: 3116916

Abstract

The distribution of fleroxacin (Ro 23-6240) in canine prostatic tissue and fluids was investigated under steady-state conditions during intravenous infusion. Mean ratios of fleroxacin concentration in tissue and fluids over concentration in plasma were 1.57 +/- 0.25 for prostatic tissue, 1.12 +/- 0.28 for prostatic secretion, and 0.93 +/- 0.14 for prostatic interstitial fluid. These levels and concentrations in urine were several times higher than the MIC for most pathogens that cause chronic bacterial prostatitis and urinary tract infection. The MICs for several isolates of Escherichia coli were only slightly affected by canine prostatic secretion, human prostatic tissue extract, and human urine. Clinical trials with fleroxacin appear justified for chronic bacterial prostatitis and urinary tract infection.

Full text

PDF
1010

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergeron M. G., Thabet M., Roy R., Lessard C., Foucault P. Norfloxacin penetration into human renal and prostatic tissues. Antimicrob Agents Chemother. 1985 Aug;28(2):349–350. doi: 10.1128/aac.28.2.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boerema J. B., Dalhoff A., Debruyne F. M. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy. 1985;31(1):13–18. doi: 10.1159/000238308. [DOI] [PubMed] [Google Scholar]
  3. Bologna M., Vaggi L., Forchetti C. M., Martini E. Bactericidal intraprostatic concentrations of norfloxacin. Lancet. 1983 Jul 30;2(8344):280–280. doi: 10.1016/s0140-6736(83)90258-1. [DOI] [PubMed] [Google Scholar]
  4. Chin N. X., Brittain D. C., Neu H. C. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother. 1986 Apr;29(4):675–680. doi: 10.1128/aac.29.4.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dalhoff A., Weidner W. Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol. 1984 Aug;3(4):360–362. doi: 10.1007/BF01977495. [DOI] [PubMed] [Google Scholar]
  6. Fair W. R., Cordonnier J. J. The pH of prostatic fluid: a reappraisal and therapeutic implications. J Urol. 1978 Dec;120(6):695–698. doi: 10.1016/s0022-5347(17)57333-4. [DOI] [PubMed] [Google Scholar]
  7. Frimodt-Møller P. C., Dørflinger T., Madsen P. O. Amifloxacin distribution in the dog prostate. Prostate. 1985;6(2):163–168. doi: 10.1002/pros.2990060206. [DOI] [PubMed] [Google Scholar]
  8. Frimodt-Møller P. C., Dørflinger T., Madsen P. O. Distribution of ciprofloxacin in the dog prostate and various tissues. Urol Res. 1984;12(6):283–286. doi: 10.1007/BF00258036. [DOI] [PubMed] [Google Scholar]
  9. Hirai K., Aoyama H., Hosaka M., Oomori Y., Niwata Y., Suzue S., Irikura T. In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative. Antimicrob Agents Chemother. 1986 Jun;29(6):1059–1066. doi: 10.1128/aac.29.6.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hoogkamp-Korstanje J. A., van Oort H. J., Schipper J. J., van der Wal T. Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens. J Antimicrob Chemother. 1984 Dec;14(6):641–645. doi: 10.1093/jac/14.6.641. [DOI] [PubMed] [Google Scholar]
  11. Kusajima H., Ishikawa N., Machida M., Uchida H., Irikura T. Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother. 1986 Aug;30(2):304–309. doi: 10.1128/aac.30.2.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Madsen P. O., Baumueller A., Hoyme U. Experimental models for determination of antimicrobials in prostatic tissue, interstitial fluid and secretion. Scand J Infect Dis Suppl. 1978;(14):145–150. [PubMed] [Google Scholar]
  13. Maigaard S., Frimodt-Möller N., Hoyme U., Madsen P. O. Rosoxacin and cinoxacin distribution in prostate, vagina, and female urethra. An experimental study in dogs. Invest Urol. 1979 Sep;17(2):149–152. [PubMed] [Google Scholar]
  14. Manek N., Andrews J. M., Wise R. In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother. 1986 Aug;30(2):330–332. doi: 10.1128/aac.30.2.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Meares E. M., Jr Prostatitis syndromes: new perspectives about old woes. J Urol. 1980 Feb;123(2):141–147. doi: 10.1016/s0022-5347(17)55828-0. [DOI] [PubMed] [Google Scholar]
  16. Meares E. M., Stamey T. A. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968 Mar;5(5):492–518. [PubMed] [Google Scholar]
  17. Mett H., Gyr K., Zak O., Vosbeck K. Duodeno-pancreatic secretions enhance bactericidal activity of antimicrobial drugs. Antimicrob Agents Chemother. 1984 Jul;26(1):35–38. doi: 10.1128/aac.26.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Stamey T. A., Meares E. M., Jr, Winningham D. G. Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol. 1970 Feb;103(2):187–194. doi: 10.1016/s0022-5347(17)61919-0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES